CHRS

1.15

4.17% -0.05

Dopo l'orario di chiusura: 1.27 0.12 +10.43%

Coherus Oncology Inc (CHRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CHRS Giù? Forum Previsione

Precedente Chiudi:

$1.20

Aprire:

$1.2

Volume 24 ore:

1.11M

Relative Volume:

1.12

Capitalizzazione di mercato:

$177.68M

Reddito:

$46.88M

Utile/perdita netta:

$-172.66M

Rapporto P/E:

-0.9229

EPS:

-1.2461

Flusso di cassa netto:

$-170.57M

1 W Prestazione:

-7.26%

1M Prestazione:

-17.86%

6M Prestazione:

-28.57%

1 anno Prestazione:

+9.52%

Intervallo 1D:

$1.13

$1.2001

Intervallo di 1 settimana:

$1.13

$1.2599

Portata 52W:

$1.03

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Nome

Coherus Oncology Inc

Settore

Healthcare (1082)

Industria

Biotechnology (606)

Telefono

(650) 649-3530

Indirizzo

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Dipendente

145

Cinguettio

@coherus_bio

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CHRS Coherus Oncology Inc	1.15	185.40M	46.88M	-172.66M	-170.57M	-1.2461
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-23	Iniziato	Oppenheimer	Outperform
2025-09-04	Aggiornamento	Maxim Group	Hold → Buy
2024-08-16	Downgrade	UBS	Buy → Neutral
2023-11-17	Iniziato	Robert W. Baird	Outperform
2023-11-08	Downgrade	Maxim Group	Buy → Hold
2023-07-24	Iniziato	Citigroup	Buy
2023-05-01	Iniziato	Truist	Buy
2023-03-28	Aggiornamento	UBS	Neutral → Buy
2022-06-14	Iniziato	UBS	Neutral
2022-03-07	Downgrade	JP Morgan	Overweight → Neutral
2020-07-16	Iniziato	BofA Securities	Neutral
2020-04-17	Iniziato	SunTrust	Buy
2019-08-13	Iniziato	Mizuho	Buy
2019-08-02	Reiterato	H.C. Wainwright	Buy
2019-08-02	Reiterato	Maxim Group	Buy
2019-06-11	Iniziato	Barclays	Overweight
2019-05-07	Iniziato	H.C. Wainwright	Buy
2018-08-28	Iniziato	H.C. Wainwright	Buy
2018-03-09	Reiterato	Maxim Group	Buy
2017-08-08	Reiterato	JP Morgan	Overweight
2017-06-13	Reiterato	Maxim Group	Buy
2017-05-05	Iniziato	BMO Capital Markets	Outperform
2016-10-19	Iniziato	Robert W. Baird	Outperform
2016-09-07	Iniziato	Maxim Group	Buy
2016-07-27	Iniziato	Citigroup	Buy
2016-01-20	Iniziato	Credit Suisse	Outperform

Mostra tutto

Coherus Oncology Inc Borsa (CHRS) Ultime notizie

06:05 AM

Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com Canada

06:05 AM

05:55 AM

Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com

05:55 AM

05:36 AM

Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - TradingView

05:36 AM

05:33 AM

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire

05:33 AM

01:17 AM

Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria

Aug 07, 2026

Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim - Moomoo

Aug 07, 2026

Aug 06, 2026

H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 06, 2026

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 06, 2026

Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Value ETF - dars.gov.et

Aug 06, 2026